Dr. Reddy's Laboratories Ltd. Sponsored ADR Stock
Dr. Reddy's Laboratories Ltd. Sponsored ADR Stock price
Key metrics
| Market capitalization | $13.39b |
| Enterprise Value | $12.62b |
| P/E (TTM) P/E ratio | 20.00 |
| EV/FCF (TTM) EV/FCF | 43.22 |
| EV/Sales (TTM) EV/Sales | 3.64 |
| P/S ratio (TTM) P/S ratio | 3.86 |
| P/B ratio (TTM) P/B ratio | 3.79 |
| Dividend yield | 0.59% |
| Last dividend (FY25) | $0.48 |
Is Dr. Reddy's Laboratories Ltd. Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.
Dr. Reddy's Laboratories Ltd. Sponsored ADR Stock Analysis
Analyst Opinions
36 Analysts have issued a Dr. Reddy's Laboratories Ltd. Sponsored ADR forecast:
Analyst Opinions
36 Analysts have issued a Dr. Reddy's Laboratories Ltd. Sponsored ADR forecast:
Financial data from Dr. Reddy's Laboratories Ltd. Sponsored ADR
| Jun '24 | |
| Current assets | 3,228 3,228 |
| Fixed assets | 1,752 1,752 |
| Total Assets | 4,980 4,980 |
| Jun '24 | |
| Equity | 3,533 3,533 |
| Debt capital | 1,447 1,447 |
| Total Capital | 4,980 4,980 |
In millions USD.
Don't miss a Thing! We will send you all news about Dr. Reddy's Laboratories Ltd. Sponsored ADR directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Dr. Reddy's Laboratories Ltd. Sponsored ADR Stock News
Company Profile
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
| Head office | India |
| CEO | Erez Israeli |
| Employees | 27,048 |
| Founded | 1984 |
| Website | www.drreddys.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
